Related Experiment Video
Updated: Sep 19, 2025

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
A Super-Enhancer-Driven Transcriptional Regulatory Circuit Underlying Abiraterone Resistance in Castration-Resistant
Liling Jiang1,2, Jiamin Wang3, Guanjie Peng1,4
1Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, Sino-French Hoffmann Institute, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, Guangdong, 511436, P. R. China.
Abstract:
Castration-resistant prostate cancer (CRPC) remains the leading cause of mortality among prostate cancer patients. While second-generation androgen receptor (AR) pathway-targeted therapies, such as Abiraterone, have significantly improved survival outcomes, resistance to these treatments ultimately emerges, posing a critical challenge. Understanding the mechanisms underlying Abiraterone resistance is essential for developing strategies to enhance patient outcomes. In this study, a super-enhancer (SE)-driven transcriptional regulatory circuit is identified involving BCL6, NFIB, and SMAD3 that facilitates Abiraterone resistance in CRPC. Through comprehensive analyses of SE expression profiles in Abiraterone-resistant CRPC cells and their parental counterparts, it is revealed that this circuit plays a pivotal role in resistance progression. Mechanistically, BCL6, NFIB, and SMAD3 synergistically remodel the transcriptional landscape of resistant CRPC cells, driving resistance by regulating cholesterol biosynthesis and cell cycle pathways. The findings provide critical insights into the transcriptional dysregulation underlying Abiraterone resistance and highlight potential therapeutic strategies to counteract treatment resistance in CRPC, ultimately aiming to improve patient survival and quality of life.
Insights
A new study identifies a BCL6, NFIB, and SMAD3 circuit driving resistance to Abiraterone treatment in castration-resistant prostate cancer (CRPC). This discovery offers potential strategies to overcome treatment failure and improve patient survival.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Castration-resistant prostate cancer (CRPC) is a major cause of cancer mortality.
- Abiraterone, an androgen receptor (AR) pathway inhibitor, improves survival but resistance develops.
- Understanding resistance mechanisms is crucial for improving CRPC treatment outcomes.
Purpose of the Study:
- To identify the molecular mechanisms driving Abiraterone resistance in CRPC.
- To investigate the role of super-enhancers (SEs) in regulating resistance pathways.
- To uncover potential therapeutic targets for overcoming Abiraterone resistance.
Main Methods:
- Analysis of SE expression profiles in Abiraterone-resistant CRPC cells and parental cells.
- Identification of key transcriptional regulators involved in resistance.
- Investigation of the functional roles of identified regulators in cellular pathways.
Main Results:
- A novel SE-driven transcriptional circuit involving BCL6, NFIB, and SMAD3 was identified.
- This circuit is upregulated in Abiraterone-resistant CRPC cells.
- BCL6, NFIB, and SMAD3 synergistically regulate cholesterol biosynthesis and cell cycle pathways, promoting resistance.
Conclusions:
- The BCL6-NFIB-SMAD3 circuit is a key driver of Abiraterone resistance in CRPC.
- Targeting this circuit may offer a strategy to resensitize CRPC to Abiraterone therapy.
- These findings provide critical insights for developing novel therapeutic approaches to improve CRPC patient outcomes.
More Related Videos
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
08:36Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses
Published on: October 24, 2019
Related Concept Videos
Master Transcription Regulators
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation
RNA Polymerase II Accessory Proteins
Co-activators and Co-repressors
Cell Specific Gene Expression